SANOFI-GENZYME

In Specialty Care our mission is to help people with debilitating and complex conditions in rare diseases, neurology, oncology and immunology. These conditions are often difficult to diagnose and treat. With over 40 years working alongside the rare disease community, we have been a pioneer and innovator in rare genetic diseases. Lysosomal storage disorders (LSDs) are a group of extremely rare diseases with high unmet need, they are an area of expertise for us, particularly Gaucher, Fabry, ASMD, Pompe and Mucopolysaccharidosis (MPS) I diseases. Sanofi is grounded in both the science behind these conditions as well as the experiences of the people who face them. We are committed to improving the health and lives of people with rare diseases around the world through groundbreaking science.

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.

Role within Screen4Care

Since January 2026 Sanofi assumes the industry lead of the Innovative Medicines Initiative consortium SCREEN4CARE, building on our partnership since its inception in 2021. Sanofi has an active participation and contribution to most work packages in Screen4Care.